Abstract:Brain perineuronal nets (PNNs) are vital for neurocircuit stability and changes in their abundance and composition have been linked to Alzheimer's disease (AD) progression. In this work, we investigated age‐associated PNN changes in transgenic mice with tauopathy‐related AD neuropathology. 9‐month‐old PS19 (P301S) mice exhibited changes in PNN chondroitin sulfate‐glycosaminoglycan (CS‐GAG) composition and abundance, but not the underlying CS proteoglycan (CSPG) core proteins, in association with pTau, gliosis, and neurodegeneration. In contrast, Tau4RTg2652 mice showed stable PNNs despite pTau accumulation, emphasizing the importance of neuroinflammation on PNN glycan integrity in AD. Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by clinical symptoms of memory and cognitive deficiencies. Postmortem evaluation of AD brain tissue shows proteinopathy that closely associate with the progression of this dementing disorder, including the accumulation of extracellular beta amyloid (Aβ) and intracellular hyperphosphorylated tau (pTau) with neurofibrillary tangles (NFTs). Current therapies targeting Aβ have limited clinical efficacy and life‐threatening side effects and highlight the need for alternative treatments targeting pTau and other pathophysiologic mechanisms driving AD pathogenesis. The brain's extracellular matrices (ECM), particularly perineuronal nets (PNNs), play a crucial role in brain functioning and neurocircuit stability, and reorganization of these unique PNN matrices has been associated with the progression of AD and accumulation of pTau in humans. We hypothesize that AD‐associated changes in PNNs may in part be driven by the accumulation of pTau within the brain. In this work, we investigated whether the presence of pTau influenced PNN structural integrity and PNN chondroitin sulfate‐glycosaminoglycan (CS‐GAG) compositional changes in two transgenic mouse models expressing tauopathy‐related AD pathology, PS19 (P301S) and Tau4RTg2652 mice. We show that PS19 mice exhibit an age‐dependent loss of hippocampal PNN CS‐GAGs, but not the underlying aggrecan core protein structures, in association with pTau accumulation, gliosis, and neurodegeneration. The loss of PNN CS‐GAGs were linked to shifts in CS‐GAG sulfation patterns to favor the neuroregenerative isomer, 2S6S‐CS. Conversely, Tau4RTg2652 mice exhibit stable PNN structures and normal CS‐GAG isomer composition despite robust pTau accumulation, suggesting a critical interaction between neuronal PNN glycan integrity and neighboring glial cell activation. Overall, our findings provide insights into the complex relationship between PNN CS‐GAGs, pTau pathology, gliosis, and neurodegeneration in mouse models of tauopathy, and offer new therapeutic insights and targets for AD treatment.

Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease

Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation

Phosphorylation at serine 214 correlates with tau seeding activity in an age-dependent manner in two mouse models for tauopathies and is required for tau transsynaptic propagation.

Protein homeostasis gene dysregulation in pretangle-bearing nucleus basalis neurons during the progression of Alzheimer's disease.

Pathological Tau From Alzheimer's Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo .

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

Uncovering the Effect of Ps202/pt205/ps208 Triple Phosphorylations on the Conformational Features of the Key Fragment G192-T212 of Tau Protein

Tau protein profiling in tauopathies: a human brain study

Uncovering elevated tau TPP motif phosphorylation in the brain of Alzheimer's disease patients

The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death

Accumulation of pTau231 at the Postsynaptic Density in Early Alzheimer's Disease

Super-Resolution Imaging Uncovers Nanoscale Tau Aggregate Hyperphosphorylation Patterns in Human Alzheimer’s Disease Brain Tissue

Regional Analysis of Differently Phosphorylated Tau Proteins in Brains from Patients with Alzheimer’s Disease

Tau P301L disengages from the proteosome core complex and neurogranin coincident with enhanced neuronal network excitability

The Relationship between p-tau217, p-tau231, and p-tau205 in the Human Brain Is Affected by the Cellular Environment and Alzheimer's Disease Pathology

Perineuronal net deglycosylation associates with tauopathy‐induced gliosis and neurodegeneration

Threonine175, a novel pathological phosphorylation site on tau protein linked to multiple tauopathies

Phosphorylation and O-GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates

Site-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer’s mice

Tau phosphosignatures discriminate Alzheimer Disease from other tauopathies

Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia